- Home
- /
- Treatment
- /
- Page 41
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 (HAO1) mRNA | Primary Hyperoxaluria Type 1 | Alnylam Pharmaceuticals, Inc.;300 Third Street;Cambridge, Massachusetts, 02142 | February 8, 2016 | |
Evinacumab | Treat of homozygous familial hypercholesterolemia | Regeneron Pharmaceuticals, Inc.;777 Old Saw Mill River Road;Tarrytown, New York, 10591 | February 8, 2016 | |
Glyburide | Acute subarachnoid hemorrhage | Remedy Pharmaceuticals, Inc.;233 Broadway, Suite 1750;New York, New York, 10279 | February 8, 2016 | |
Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4’’-(pentyloxy)[1,1’:4’,1’’-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine] | Candidemia and invasive candidiasis infections caused by susceptible Candida spp | Cidara Therapeutics, Inc.;6310 Nancy Ridge Drive, Suite 101;San Diego, California, 92121 | February 8, 2016 | |
Dabrafenib | Glioma | Novartis Pharmaceuticals Corporation;1 Health Plaza, Bldg 337;East Hanover, New Jersey, 07936 | February 8, 2016 | |
Solnatide | Generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive PHA-I or PHA-IB) | Apeptico Forschung und Entwicklung GmbH;Mariahilferstrabe 136, Top 1150;Vienna | February 8, 2016 | |
4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide | Retinitis pigmentosa | Shire HGT, Inc.;300 Shire Way;Lexington, Massachusetts, 02421 | February 8, 2016 | |
Echinocandin B,1-[(4R,5R)-4-hydroxy-N2-[[4��-(pentyloxy)[1,1�:4�,1��-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine] | Candidemia and invasive candidiasis infections caused by susceptible Candida spp | Cidara Therapeutics, Inc.;6310 Nancy Ridge Drive, Suite 101;San Diego, California, 92121 | February 8, 2016 | |
Eltoprazine HCl | Levodopa-induced dyskinesia associated with Parkinson's disease | Amarantus BioScience Holdings, Inc.;655 Montgomery St., Suite 900;San Francisco, California, 94111 | February 8, 2016 | |
Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH | Ovarian cancer | Soricimed Biopharma Inc.;18 Botsford Street, Suite 201;Moncton, New Brunswick | February 4, 2016 | |
Allogeneic Epstein-Barr virus cytotoxic T lymphocytes | Epstein-Barr virus-positive post-transplant lymphoproliferative disorders | ATARA Biotherapeutics, Inc.;4360 Park Terrace Drive, Suite 100;Westlake Village, California, 91361 | February 4, 2016 | |
Solnatide | Primary graft dysfunction following lung transplantation | Apeptico Forschung und Entwicklung GmbH;c/o mingo bueros, 1150;Vienna | February 4, 2016 | |
Human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A | Pediatric patients 0 to <18 yrs of age with oligoarticular-course and polyarticular-course juvenile idiopathic arthritis | AbbVie, Inc.;1 North Waukegan Road;North Chicago, Illinois, 60064 | February 4, 2016 | |
Venetoclax | Acute myeloid leukemia | AbbVie Inc.;1 Waukegan Road, Dept PA77, Bldg. AP30;North Chicago, Illinois, 60044 | February 4, 2016 | |
Tazemetostat | Malignant rhabdoid tumors (MRTs) | Epizyme Inc.;400 Technology Square, 4th Floor;Cambridge, Massachusetts, 02139 | February 4, 2016 | |
Midazolam | Status epilepticus | Meridian Medical Technologies, Inc.;A Pfizer Company, 6350 Stevens Forest Road;Columbia, Maryland, 21046 | February 4, 2016 | |
Afamelanotide | Cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease) | Clinuvel Inc.;40 Worth Street, Suite 1053;New York, New York, 10013 | February 4, 2016 | |
Somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells. | Prevention of organ rejection in living donor kidney transplant recipients | Regenerex LLC;570 South Preston Street, Suite 404;Louisville, Kentucky, 40202 | February 4, 2016 | |
Oligodendrocyte progenitor cells | Acute spinal cord injury | Asterias Biotherapeutics;6300 Dumbarton Circle;Fremont, California, 94555 | February 2, 2016 | |
Ibrutinib | Patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma) | Pharmacyclics, LLC;995 E. Arques Avenue;Sunnyvale, California, 94085 | February 2, 2016 | |
Bevacizumab | Malignant pleural mesothelioma | Genentech, Inc.;1 DNA Way;South San Francisco, California, 94080 | January 27, 2016 | |
HLA-A2-selective gp100-specific T cell redirector | Uveal melanoma | Immunocore Ltd;Milton Park, 90 Park Drive;Milton | January 21, 2016 | |
Small molecule inhibitor of Exon 17 Mutant KIT | Mastocytosis | Blueprint Medicines Corporation;38 Sidney Street, Suite 200;Cambridge, Massachusetts, 02139 | January 21, 2016 | |
Endothelin receptor B antagonist | Malignant melanoma Stages IIB to IV | ENB Therapeutics, LLC;166 5th Avenue, 2nd Floor;New York, New York, 10010 | January 21, 2016 | |
Thioureidobutyronitrile | Pancreatic cancer | Innovation Pharmaceuticals, Inc.;100 Cummings Center, Suite 151-B;Beverly, Massachusetts, 01915 | January 20, 2016 |